• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Indivior PLC

    12/22/25 4:19:54 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $INDV alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Indivior PLC

    (Name of Issuer)


    Ordinary Shares, $0.50 nominal value per share

    (Title of Class of Securities)


    G4766E116

    (CUSIP Number)


    12/15/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    G4766E116


    1Names of Reporting Persons

    Millennium Management LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,461,370.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,461,370.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,461,370.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    2.0 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    G4766E116


    1Names of Reporting Persons

    Millennium Group Management LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,461,370.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,461,370.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,461,370.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    2.0 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    G4766E116


    1Names of Reporting Persons

    Israel A. Englander
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,461,370.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,461,370.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,461,370.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    2.0 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Indivior PLC
    (b)Address of issuer's principal executive offices:

    10710 Midlothian Turnpike, Suite 125, North Chesterfield, Virginia 23235
    Item 2. 
    (a)Name of person filing:

    Millennium Management LLC Millennium Group Management LLC Israel A. Englander
    (b)Address or principal business office or, if none, residence:

    Millennium Management LLC 399 Park Avenue New York, New York 10022 Millennium Group Management LLC 399 Park Avenue New York, New York 10022 Israel A. Englander c/o Millennium Management LLC 399 Park Avenue New York, New York 10022
    (c)Citizenship:

    Millennium Management LLC - Delaware Millennium Group Management LLC - Delaware Israel A. Englander - United States
    (d)Title of class of securities:

    Ordinary Shares, $0.50 nominal value per share
    (e)CUSIP No.:

    G4766E116
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See response to Item 9 on each cover page. After acquiring beneficial ownership of more than 5% of the outstanding Ordinary Shares on December 15, 2025, the reporting persons ceased to be beneficial owners of more than 5% of the outstanding Ordinary Shares by the date of this filing.
    (b)Percent of class:

    See response to Item 11 on each cover page.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See response to Item 5 on each cover page.

     (ii) Shared power to vote or to direct the vote:

    See response to Item 6 on each cover page.

     (iii) Sole power to dispose or to direct the disposition of:

    See response to Item 7 on each cover page.

     (iv) Shared power to dispose or to direct the disposition of:

    See response to Item 8 on each cover page. The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    See Exhibit I
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Millennium Management LLC
     
    Signature:/s/ Gil Raviv
    Name/Title:Gil Raviv, Global General Counsel
    Date:12/19/2025
     
    Millennium Group Management LLC
     
    Signature:/s/ Gil Raviv
    Name/Title:Gil Raviv, Global General Counsel
    Date:12/19/2025
     
    Israel A. Englander
     
    Signature:/s/ Israel A. Englander
    Name/Title:Israel A. Englander
    Date:12/19/2025
    Exhibit Information

    Exhibit I: Joint Filing Agreement, dated as of December 19, 2025, by and among Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.

    Get the next $INDV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $INDV

    DatePrice TargetRatingAnalyst
    8/6/2025$27.00Buy
    H.C. Wainwright
    7/22/2025$20.00Buy
    Jefferies
    1/28/2025$16.00Buy
    Rodman & Renshaw
    7/23/2024$22.00Overweight
    Piper Sandler
    4/3/2024$37.00Buy
    Craig Hallum
    7/13/2023$35.00Outperform
    Northland Capital
    More analyst ratings

    $INDV
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Indivior PLC

    SCHEDULE 13G - INDIVIOR PLC (0001625297) (Subject)

    12/22/25 4:19:54 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Indivior PLC filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - INDIVIOR PLC (0001625297) (Filer)

    12/22/25 7:03:43 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Indivior PLC filed SEC Form 8-K: Leadership Update

    8-K - INDIVIOR PLC (0001625297) (Filer)

    12/18/25 4:04:49 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INDV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Indivior with a new price target

    H.C. Wainwright initiated coverage of Indivior with a rating of Buy and set a new price target of $27.00

    8/6/25 8:01:45 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies resumed coverage on Indivior with a new price target

    Jefferies resumed coverage of Indivior with a rating of Buy and set a new price target of $20.00

    7/22/25 7:52:44 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rodman & Renshaw initiated coverage on Indivior with a new price target

    Rodman & Renshaw initiated coverage of Indivior with a rating of Buy and set a new price target of $16.00

    1/28/25 7:14:13 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INDV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Indivior Announces Inclusion in the S&P SmallCap 600® Index

    RICHMOND, Va., Dec. 22, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ:INDV) ("Indivior PLC" or the "Company") today announced that it will be added to the S&P SmallCap 600® index, effective today. "Indivior's inclusion in the S&P SmallCap 600 index marks an important milestone for Indivior that further aligns our capital markets presence with our sharpened U.S. business profile," said Joe Ciaffoni, Chief Executive Officer. "We are committed to growing SUBLOCADE®, our number one prescribed, first-in-class long-acting injectable treatment for moderate to severe opioid use disorder,

    12/22/25 7:00:00 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New Study Shows Extended-Release Buprenorphine Safely Delivers Rapid, Clinically Meaningful Reductions in Opioid Use and Supports Abstinence in High-Risk Populations

    Both monthly maintenance doses (100 mg and 300 mg) improved opioid abstinence and were well-tolerated with no new safety signals identified.Post-hoc analyses indicated the 300-mg monthly maintenance dose performed significantly better than the 100-mg monthly dose in participants reporting high-frequency fentanyl use.RICHMOND, Va., Dec. 17, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ:INDV) today announced results from a randomized, double-blind clinical trial published in JAMA Network Open. The study found that both the 100-mg and 300-mg monthly maintenance doses of SUBLOCADE® (extended-release buprenorphine) rapidly reduced opioid use and improved opioid abstinence and were well tolerated, wit

    12/17/25 11:30:00 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CRH, Carvana and Comfort Systems USA Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, Dec. 5, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 22, to coincide with the quarterly rebalance. The changes ensure that each index is more representative of its market capitalization range. The companies being removed from the S&P SmallCap 600 are no longer representative of the small-cap market space.  Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector Dec 22, 2025  S&P 500 Addition CRH CRH Mat

    12/5/25 5:49:00 PM ET
    $ASIX
    $BAH
    $BWA
    Major Chemicals
    Industrials
    Professional Services
    Consumer Discretionary

    $INDV
    Leadership Updates

    Live Leadership Updates

    View All

    CRH, Carvana and Comfort Systems USA Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, Dec. 5, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 22, to coincide with the quarterly rebalance. The changes ensure that each index is more representative of its market capitalization range. The companies being removed from the S&P SmallCap 600 are no longer representative of the small-cap market space.  Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector Dec 22, 2025  S&P 500 Addition CRH CRH Mat

    12/5/25 5:49:00 PM ET
    $ASIX
    $BAH
    $BWA
    Major Chemicals
    Industrials
    Professional Services
    Consumer Discretionary

    Indivior Appoints Vanessa Procter as Executive Vice President of Corporate Affairs

    RICHMOND, Va., July 8, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) today announced the appointment of Vanessa Procter as Executive Vice President of Corporate Affairs, effective July 7, 2025. Vanessa is a seasoned corporate affairs leader with extensive experience in the biopharmaceutical industry, and will be responsible for Corporate Communications, Government Affairs, Policy and Advocacy at Indivior. "We are excited to welcome Vanessa to the Indivior team," said Joe Ciaffoni, Chief Executive Officer. "Vanessa has an impressive track record of aligning teams to pr

    7/8/25 8:00:00 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Indivior Appoints Tony Kingsley to the Board of Directors

    RICHMOND, Va., June 24, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) today announced the appointment of Tony Kingsley to the Board of Directors as an Independent Non-Executive Director, effective July 1, 2025. Mr. Kingsley was appointed pursuant to Indivior's relationship agreement with affiliates of Oaktree Capital Management, L.P., who supported his appointment. Tony Kingsley is an accomplished biopharmaceutical executive with a distinguished track record of building and leading organizations across multiple scientific disciplines, therapeutic areas, and stages of

    6/24/25 4:12:00 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INDV
    Financials

    Live finance-specific insights

    View All

    Indivior Reports Third Quarter 2025 Financial Results and Raises Full-Year 2025 Financial Guidance

    Q3'25 Total Net Revenue of $314m, up 2% YOY; Q3'25 SUBLOCADE® Net Revenue of $219m, up 15% YOYAnnounces the Optimization of Rest of World (ROW) Business Discontinued the Sales and Marketing Support of OPVEE®Expect Annual Operating Expense Savings of at Least $150m in 2026On Track to Enter Phase II of the Indivior Action Agenda — Accelerate — January 1, 2026Conference Call Scheduled for Today at 8:00 A.M. EasternRICHMOND, Va., Oct. 30, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ:INDV) today reported its financial results for the third quarter ended September 30, 2025, and provided a business update.

    10/30/25 7:00:00 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Indivior to Report Third Quarter 2025 Financial Results and Host Webcast on October 30th

    RICHMOND, Va., Oct. 16, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ:INDV) today announced that it will report its third quarter 2025 financial results on Thursday, October 30, 2025, at 7:00 a.m. U.S. ET. Following the release of the financial results, Joe Ciaffoni, Chief Executive Officer, and other members of Indivior's leadership team will host a presentation via live webcast at 8:00 a.m. U.S. ET. Access to the Live Webcast Presentation: The webcast event and materials can be accessed on the "Investors" section of the company's website at www.indivior.com before the event begi

    10/16/25 4:04:00 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Indivior Reports Second Quarter 2025 Financial Results and Raises FY 2025 Financial Guidance

    Q2'25 Total Net Revenue of $302m; Q2'25 SUBLOCADE® Net Revenue of $209m, up 9% Year-over-YearIndivior Action Agenda Underway to Strengthen Business and Generate Operational Momentum Conference Call Scheduled for Today at 8:00 A.M. EDTRICHMOND, Va., July 31, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ:INDV) today reported its financial results for the second quarter ended June 30, 2025, and provided a business update. "SUBLOCADE® net revenue and pricing stability in SUBOXONE® Film in the U.S. drove solid results in the second quarter, leading us to raise our 2025 financial guidan

    7/31/25 7:00:00 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INDV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Indivior PLC

    SC 13G - INDIVIOR PLC (0001625297) (Subject)

    11/15/24 6:03:54 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Indivior PLC

    SC 13G/A - INDIVIOR PLC (0001625297) (Subject)

    11/14/24 5:00:25 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Indivior PLC

    SC 13D/A - INDIVIOR PLC (0001625297) (Subject)

    11/7/24 8:23:16 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care